We hypothesized that GB4-BPL could actively target the codelivery of pPTEN and siCXCR2 to bone metastasis sites with high efficiency and low toxicity, restoring Pten function and reversing the immunosuppressive tumor microenvironment. Here, PTEN is linked to neoplasm.